New York State Teachers Retirement System Sells 2,616 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

New York State Teachers Retirement System decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 97,811 shares of the biopharmaceutical company's stock after selling 2,616 shares during the period. New York State Teachers Retirement System owned about 0.09% of Regeneron Pharmaceuticals worth $69,674,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in REGN. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Private Wealth Management Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 39 shares during the period. Finally, Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on REGN shares. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Citigroup decreased their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Royal Bank of Canada decreased their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. Finally, Sanford C. Bernstein decreased their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Trading Up 1.0 %

Shares of REGN stock traded up $6.40 during trading hours on Tuesday, reaching $680.00. The company had a trading volume of 743,097 shares, compared to its average volume of 945,916. The firm has a market cap of $74.73 billion, a price-to-earnings ratio of 17.76, a P/E/G ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. The company has a 50 day moving average of $704.64 and a 200 day moving average of $891.91.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $11.86 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.